MediciNova, Inc.
NASDAQ:MNOVBiotechnology
-$0.02 today
- Market cap
- $68.14M
- Beta
- 0.62
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.24
Volume 0.12M
Average 0.04M
MNOV Net Income
Bottom-line profit, the starting point for calculating cash from operations.
MediciNova, Inc.NASDAQ: MNOV
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $2.59M (cash outflow) fell 9.7% year over year, behind the +5.0% change in trailing-twelve-month net income. Sequentially, it fell 7.7% from the prior quarter. Over 3 fiscal years it compounded at -5.2% a year.
Context
- Net income amounted to 2928.8% of revenue in FY2025.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$10.8M (-10.0%) for the fiscal year ending Dec 2026, a slowdown from the +8.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$2.59M-7.7% QoQ
- Last fiscal yearDec 2025
- -$12M+8.6% YoY
- LTMMar 2026
- -$11.72M+5.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.7% | -4.7% | +5.0 pp |
| 1 year | +8.6% | -10.0% | -18.6 pp |
| 3-year CAGR | -5.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (12M) USD
- Year-over-year change
- -8.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12M) | -8.6% |
| FY2024 | 2024-12-31 | (11.05M) | -28.9% |
| FY2023 | 2023-12-31 | (8.57M) | +39.1% |
| FY2022 | 2022-12-31 | (14.07M) | -38.8% |
| FY2021 | 2021-12-31 | (10.13M) | — |
Net Income vs competitors
How MNOV compares with its peers on the latest reported figures
- MNOV's LTM Mar 2026 net income of $11.72M is the smallest of the 11 companies compared; the peer median is $68.07M.
- Its year-over-year change of +5.0% is the 5th highest of 11, against a peer median of -1.8%.
- Net income amounts to 1964.3% of revenue for MNOV, versus a peer median of 757.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.31M | -5.5% | +25.1% | 1360.6% | |
| LTM Mar 2026 | $104.29M | +8.2% | -6.9% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $103.27M | -65.4% | +96.0% | 2409.4% |
| LTM Mar 2026 | $102.15M | +215.2% | -46.4% | 154.4% | |
| LTM Mar 2026 | $78.34M | +28.7% | +2.0% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $77.27M | -7.7% | +35.7% | — |
| LTM Mar 2026 | $58.88M | -22.2% | -28.5% | — | |
| LTM Mar 2026 | $44.95M | -65.1% | -8.9% | — | |
| LTM Mar 2026 | $40.16M | +1.9% | +11.4% | — | |
| LTM Mar 2026 | $37.1M | +163.8% | — | 14.5% | |
| LTM Mar 2026 | $11.72M | +5.0% | -5.2% | 1964.3% | |
| Peer median (excluding MNOV) | $68.07M | -1.8% | +2.0% | 757.5% | |
Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.13M) | (14.07M) | (8.57M) | (11.05M) | (12M) |
| Depreciation & Amortization | 26.15K | 17.71K | 20.3K | 21.08K | 20.1K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.72M | 642.52K | 710.71K | 1.19M | 829.1K |
| Change in Working Capital | (1.21M) | 334.1K | 111.99K | (979.56K) | 1.17M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.03M) | 329.01K | 19.24K | (312.35K) | 459.87K |
| Other Working Capital | (181.42K) | 5.09K | 92.75K | (667.21K) | 705.15K |
| Other Non-Cash Items | 216.93K | 163.19K | 297.49K | 173.32K | 173.68K |
| Operating Cash Flow | (9.38M) | (12.91M) | (7.43M) | (10.64M) | (9.81M) |
| Capital Expenditures | (28.73K) | (5.01K) | (21.3K) | (895) | 0 |
| Acquisitions (Net) | 0 | 5.01M | 0 | 0 | 0 |
| Purchases of Investments | 0 | (59.88M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 19.88M | 39.93M | 0 | 0 |
| Other Investing Activities | 0 | (5.01M) | 0 | 198 | (2.9K) |
| Investing Cash Flow | (28.73K) | (40.01M) | 39.91M | (697) | (2.9K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 20.89M | 7.92K | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (112.26K) | 0 | 0 | 0 | 244.02K |
| Financing Cash Flow | 20.78M | 7.92K | 0 | 0 | 244.02K |
| Effect of Forex Changes | 26.55K | (16.81K) | 17.27K | 3.96K | 15.68K |
| Net Change in Cash | 11.39M | (52.93M) | 32.49M | (10.64M) | (9.55M) |
| Free Cash Flow | (9.41M) | (12.92M) | (7.45M) | (10.64M) | (9.81M) |
MediciNova, Inc.
NASDAQ:MNOV
Intrinsic Alpha fair value
Locked
Current Price
$1.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.